Patents by Inventor Vijay H. Naringrekar

Vijay H. Naringrekar has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS OF USING CTLA4Ig SUBCUTANEOUS FORMULATIONS
    Publication number: 20230277672
    Abstract: The present invention relates generally to stable formulations comprising CTLA4Ig molecules, including lyophilized, and liquid formulations for administration via various routes including, for example, routes such as intravenous (IV) and subcutaneous(SC) for treating immune system diseases and tolerance induction.
    Type: Application
    Filed: November 3, 2022
    Publication date: September 7, 2023
    Inventors: Manisha P Desai, Charles E. Dahlheim, Sunita Borsadia, Vijay H. Naringrekar, Rajesh Babulal Gandhi, Manoj Nerurkar
  • CONTROLLED RELEASE STERILE INJECTABLE ARIPIPRAZOLE FORMULATION AND METHOD
    Publication number: 20210338663
    Abstract: A controlled release sterile freeze-dried aripiprazole formulation is provided which is formed of aripiprazole of a desired mean particle size and a vehicle therefor, which upon constitution with water and intramuscular injection releases aripiprazole over a period of at least about one week and up to about eight weeks. A method for preparing the controlled release freeze-dried aripiprazole formulation, and a method for treating schizophrenia employing the above formulation are also provided.
    Type: Application
    Filed: July 16, 2021
    Publication date: November 4, 2021
    Inventors: Janusz W. KOSTANSKI, Takakuni MATSUDA, Manoj NERURKAR, Vijay H. NARINGREKAR
  • METHODS OF USING CTLA4Ig SUBCUTANEOUS FORMULATIONS
    Publication number: 20200230242
    Abstract: The present invention relates generally to stable formulations comprising CTLA4Ig molecules, including lyophilized, and liquid formulations for administration via various routes including, for example, routes such as intravenous (IV) and subcutaneous (SC) for treating immune system diseases and tolerance induction.
    Type: Application
    Filed: March 24, 2020
    Publication date: July 23, 2020
    Inventors: Manisha P. DESAI, Charles E. Dahlheim, Sunita Borsadia, Vijay H. Naringrekar, Rajesh Babulal Gandhi, Manoj Nerurkar
  • CONTROLLED RELEASE STERILE INJECTABLE ARIPIPRAZOLE FORMULATION AND METHOD
    Publication number: 20200061057
    Abstract: A controlled release sterile freeze-dried aripiprazole formulation is provided which is formed of aripiprazole of a desired mean particle size and a vehicle therefor, which upon constitution with water and intramuscular injection releases aripiprazole over a period of at least about one week and up to about eight weeks. A method for preparing the controlled release freeze-dried aripiprazole formulation, and a method for treating schizophrenia employing the above formulation are also provided.
    Type: Application
    Filed: October 30, 2019
    Publication date: February 27, 2020
    Inventors: Janusz W. KOSTANSKI, Takakuni MATSUDA, Manoj NERURKAR, Vijay H. NARINGREKAR
  • Stable subcutaneous protein formulations and uses thereof
    Patent number: 10265401
    Abstract: The present invention relates generally to stable formulations comprising CTLA4Ig molecules, including lyophilized, and liquid formulations for administration via various routes including, for example, routes such as intravenous (IV) and subcutaneous (SC) for treating immune system diseases and tolerance induction.
    Type: Grant
    Filed: March 10, 2016
    Date of Patent: April 23, 2019
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Manisha P Desai, Charles E Dahlheim, Sunita Borsadia, Vijay H Naringrekar, Rajesh Babulal Gandhi, Manoj Nerurkar
  • STABLE SUBCUTANEOUS PROTEIN FORMULATIONS AND USES THEREOF
    Publication number: 20180360965
    Abstract: The present invention relates generally to stable formulations comprising CTLA4Ig molecules, including lyophilized, and liquid formulations for administration via various routes including, for example, routes such as intravenous (IV) and subcutaneous (SC) for treating immune system diseases and tolerance induction.
    Type: Application
    Filed: September 4, 2018
    Publication date: December 20, 2018
    Inventors: Manisha P. Desai, Charles E. Dahlheim, Sunita Borsadia, Vijay H Naringrekar, Rajesh Babulal Gandhi, Manoj Nerurkar
  • CONTROLLED RELEASE STERILE INJECTABLE ARIPIPRAZOLE FORMULATON AND METHOD
    Publication number: 20170348308
    Abstract: A controlled release sterile freeze-dried aripiprazole formulation is provided which is formed of aripiprazole of a desired mean particle size and a vehicle therefor, which upon constitution with water and intramuscular injection releases aripiprazole over a period of at least about one week and up to about eight weeks. A method for preparing the controlled release freeze-dried aripiprazole formulation, and a method for treating schizophrenia employing the above formulation are also provided.
    Type: Application
    Filed: August 18, 2017
    Publication date: December 7, 2017
    Inventors: Janusz W. KOSTANSKI, Takakuni MATSUDA, Manoj NERURKAR, Vijay H. NARINGREKAR
  • Controlled release sterile injectable aripiprazole formulation and method
    Patent number: 9763935
    Abstract: A controlled release sterile freeze-dried aripiprazole formulation is provided which is formed of aripiprazole of a desired mean particle size and a vehicle thereof, which upon constitution with water and intramuscular injection releases aripiprazole over a period of at least about one week and up to about eight weeks. A method for preparing the controlled release freeze-dried aripiprazole formulation, and a method for treating schizophrenia employing the above formulation are also provided.
    Type: Grant
    Filed: October 6, 2014
    Date of Patent: September 19, 2017
    Assignee: Otsuka Pharmaceutical Co., Ltd.
    Inventors: Janusz W. Kostanski, Takakuni Matsuda, Manoj Nerurkar, Vijay H. Naringrekar
  • STABLE SUBCUTANEOUS PROTEIN FORMULATIONS AND USES THEREOF
    Publication number: 20160263223
    Abstract: The present invention relates generally to stable formulations comprising CTLA4Ig molecules, including lyophilized, and liquid formulations for administration via various routes including, for example, routes such as intravenous (IV) and subcutaneous (SC) for treating immune system diseases and tolerance induction.
    Type: Application
    Filed: March 10, 2016
    Publication date: September 15, 2016
    Inventors: Manisha P DESAI, Charles E Dahlheim, Sunita Borsadia, Vijay H Naringrekar, Rajesh Babulal Gandhi, Manoj Nerurkar
  • Stable subcutaneous protein formulations and uses thereof
    Patent number: 9309316
    Abstract: The present invention relates generally to stable formulations comprising CTLA4Ig molecules, including lyophilized, and liquid formulations for administration via various routes including, for example, routes such as intravenous (IV) and subcutaneous (SC) for treating immune system diseases and tolerance induction.
    Type: Grant
    Filed: March 12, 2013
    Date of Patent: April 12, 2016
    Assignee: Bristol-Myers Squibb Company
    Inventors: Manisha D. Dali, Charles E. Dahlheim, Sunita Borsadia, Vijay H. Naringrekar, Rajesh Babulal Gandhi, Manoj Nerurkar
  • ARIPIPRAZOLE COMPLEX FORUMLATION AND METHOD
    Publication number: 20150328335
    Abstract: An aripiprazole formulation is provided which includes the antipsychotic agent aripiprazole in the form of an inclusion complex in a ?-cyclodextrin, preferably, sulfobutyl ether ?-cyclodextrin (SBECD), which in the form of an injectable produces reversible generally minimal to mild irritation at the intramuscular injection site. A method for minimizing or reducing irritation caused by aripiprazole at an intramuscular injection site and a method for treating schizophrenia employing the above formulation are also provided.
    Type: Application
    Filed: March 3, 2015
    Publication date: November 19, 2015
    Inventors: Manoj Nerurkar, Vijay H. Naringrekar
  • Aripiprazole complex formulation and method
    Patent number: 8999952
    Abstract: An aripiprazole formulation is provided which includes the antipsychotic agent aripiprazole in the form of an inclusion complex in a ?-cyclodextrin, preferably, sulfobutyl ether ?-cyclodextrin (SBECD), which in the form of an injectable produces reversible generally minimal to mild irritation at the intramuscular injection site. A method for minimizing or reducing irritation caused by aripiprazole at an intramuscular injection site and a method for treating schizophrenia employing the above formulation are also provided.
    Type: Grant
    Filed: April 29, 2013
    Date of Patent: April 7, 2015
    Assignee: Otsuka Pharmaceutical Co., Ltd.
    Inventors: Manoj Nerurkar, Vijay H. Naringrekar
  • Controlled release sterile injectable aripiprazole formulation and method
    Patent number: 8952013
    Abstract: A controlled release sterile freeze-dried aripiprazole formulation is provided which is formed of aripiprazole of a desired mean particle size and a vehicle therefor, which upon constitution with water and intramuscular injection releases aripiprazole over a period of at least about one week and up to about eight weeks. A method for preparing the controlled release freeze-dried aripiprazole formulation, and a method for treating schizophrenia employing the above formulation are also provided.
    Type: Grant
    Filed: December 28, 2011
    Date of Patent: February 10, 2015
    Assignee: Otsuka Pharmaceutical Co., Ltd.
    Inventors: Janusz W. Kostanski, Takakuni Matsuda, Manoj Nerurkar, Vijay H. Naringrekar
  • CONTROLLED RELEASE STERILE INJECTABLE ARIPIPRAZOLE FORMULATION AND METHOD
    Publication number: 20150024056
    Abstract: A controlled release sterile freeze-dried aripiprazole formulation is provided which is formed of aripiprazole of a desired mean particle size and a vehicle thereof, which upon constitution with water and intramuscular injection releases aripiprazole over a period of at least about one week and up to about eight weeks. A method for preparing the controlled release freeze-dried aripiprazole formulation, and a method for treating schizophrenia employing the above formulation are also provided.
    Type: Application
    Filed: October 6, 2014
    Publication date: January 22, 2015
    Applicant: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Janusz W. KOSTANSKI, Takakuni MATSUDA, Manoj NERURKAR, Vijay H. NARINGREKAR
  • Process and formulation containing epothilones and analogs thereof
    Patent number: 8871227
    Abstract: A process for formulating certain epothilones and analogs thereof for parenteral administration is provided wherein the pH of the formulation for administration can be controlled to enhance the stability and thus, potency of the epothilone, or analog thereof.
    Type: Grant
    Filed: September 11, 2009
    Date of Patent: October 28, 2014
    Assignee: Bristol-Myers Squibb Company
    Inventors: Thomas A. Haby, Uday S. Gogate, Vijay H. Naringrekar
  • Controlled release sterile injectable aripiprazole formulation and method
    Patent number: 8722679
    Abstract: A controlled release sterile freeze-dried aripiprazole formulation is provided which is formed of aripiprazole of a desired mean particle size and a vehicle therefor, which upon constitution with water and intramuscular injection releases aripiprazole over a period of at least about one week and up to about eight weeks. A method for preparing the controlled release freeze-dried aripiprazole formulation, and a method for treating schizophrenia employing the above formulation are also provided.
    Type: Grant
    Filed: October 31, 2007
    Date of Patent: May 13, 2014
    Assignee: Otsuka Pharmaceutical Co., Ltd.
    Inventors: Janusz W. Kostanski, Takakuni Matsuda, Manoj Nerurkar, Vijay H. Naringrekar
  • CONTROLLED RELEASE STERILE INJECTABLE ARIPIPRAZOLE FORMULATION AND METHOD
    Publication number: 20140018369
    Abstract: A controlled release sterile freeze-dried aripiprazole formulation is provided which is formed of aripiprazole of a desired mean particle size and a vehicle therefor, which upon constitution with water and intramuscular injection releases aripiprazole over a period of at least about one week and up to about eight weeks. A method for preparing the controlled release freeze-dried aripiprazole formulation, and a method for treating schizophrenia employing the above formulation are also provided.
    Type: Application
    Filed: September 19, 2013
    Publication date: January 16, 2014
    Applicant: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Janusz KOSTANSKI, Takakuni MATSUDA, Manoj NERURKAR, Vijay H. NARINGREKAR
  • Controlled release sterile injectable aripiprazole formulation and method
    Patent number: 8598178
    Abstract: A controlled release sterile freeze-dried aripiprazole formulation is provided which is formed of aripiprazole of a desired mean particle size and a vehicle therefor, which upon constitution with water and intramuscular injection releases aripiprazole over a period of at least about one week and up to about eight weeks. A method for preparing the controlled release freeze-dried aripiprazole formulation, and a method for treating schizophrenia employing the above formulation are also provided.
    Type: Grant
    Filed: October 31, 2007
    Date of Patent: December 3, 2013
    Assignee: Otsuka Pharmaceutical Co., Ltd.
    Inventors: Janusz W. Kostanski, Takakuni Matsuda, Manoj Nerurkar, Vijay H. Naringrekar
  • Stable protein formulations
    Patent number: 8476239
    Abstract: The present invention relates generally to stable formulations comprising CTLA4Ig molecules, including lyophilized, and liquid formulations for administration via various routes including, for example, routes such as intravenous (IV) and subcutaneous (SC) for treating immune system diseases and tolerance induction.
    Type: Grant
    Filed: December 19, 2006
    Date of Patent: July 2, 2013
    Assignee: Bristol-Myers Squibb Company
    Inventors: Manisha M. Dali, Charles E. Dahlheim, Sunita Borsadia, Vijay H. Naringrekar, Rajesh Babulal Gandhi, Manoj Nerurkar
  • CONTROLLED RELEASE STERILE INJECTABLE ARIPIPRAZOLE FORMULATION AND METHOD
    Publication number: 20120100190
    Abstract: A controlled release sterile freeze-dried aripiprazole formulation is provided which is formed of aripiprazole of a desired mean particle size and a vehicle therefor, which upon constitution with water and intramuscular injection releases aripiprazole over a period of at least about one week and up to about eight weeks. A method for preparing the controlled release freeze-dried aripiprazole formulation, and a method for treating schizophrenia employing the above formulation are also provided.
    Type: Application
    Filed: December 28, 2011
    Publication date: April 26, 2012
    Applicant: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Janusz W. Kostanski, Takakuni Matsuda, Manoj Nerurkar, Vijay H. Naringrekar